Patient Information

YESCARTA® can cause side effects that can lead to death.

Call or see your oncologist or get emergency help RIGHT AWAY if you have any of these symptoms:

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heartbeat
- Severe fatigue or weakness

Tell any healthcare provider that sees you that you are being treated with YESCARTA®.

Stay within close proximity (within 2 hours) of the location where you received your treatment for at least 4 weeks after getting YESCARTA®.

YESCARTA, the YESCARTA Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.

© 2019 Kite Pharma, Inc. All Rights Reserved. | REMS-YES-0006 07/2019 Santa Monica, CA
Important Information for Healthcare Providers

Name of treating oncologist:

Office phone:

After-hours phone:

Date of YESCARTA® (axicabtagene ciloleucel) infusion:

- This patient has received YESCARTA®, which is a CD19-directed genetically modified autologous T-cell immunotherapy

- YESCARTA® can cause cytokine release syndrome (CRS) and neurologic toxicities, which may be fatal or life threatening. CRS may involve any organ system

- Contact the patient’s oncologist immediately for further information